Yüklüyor......
Enhanced PI3K p110α signaling confers acquired lapatinib resistance which can be effectively reversed by a p110α-selective PI3K inhibitor
While the HER2-targeting agents trastuzumab and lapatinib have improved the survival of patients with HER2-positive breast cancer, resistance to these targeted therapies is a major challenge. To investigate mechanisms of acquired lapatinib resistance, we generated acquired lapatinib resistance cell...
Kaydedildi:
| Asıl Yazarlar: | , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2013
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3902650/ https://ncbi.nlm.nih.gov/pubmed/24249715 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-13-0518 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|